Ruitang Deng

Ruitang Deng

Auto-generated profile, based on publicly available information

Ruitang Deng

Univ Rhode Isl, Coll Pharm, Dept Biomed & Pharmaceut Sci, 7 Greenhouse Rd, Kingston, RI 02881 USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
SYSangmin You
Sangmin You
ACAi-Min Cui
Ai-Min Cui
SHSyed F. Hashmi
Syed F. Hashmi
XZXinmu Zhang
Xinmu Zhang
CNChristina Nadolny
Christina Nadolny
RDRuitang Deng
Ruitang Deng
Preterm birth (PTB) is the leading cause of perinatal mortality and newborn complications. Bile acids are recognized as signaling molecules regulating a myriad of cellular and metabolic activities but have not been etiologically linked to PTB. In this study, a hospital-based cohort study with 36,755 pregnant women is conducted. We find that serum total bile acid levels directly correlate with the PTB rates regardless of the characteristics of the subjects and etiologies of liver disorders. Consistent with the findings from pregnant women, PTB is successfully reproduced in mice with liver injuries and dysregulated bile acids. More importantly, bile acids dose-dependently induce PTB with minimal hepatotoxicity. Furthermore, restoring bile acid homeostasis by farnesoid X receptor activation markedly reduces PTB and dramatically improves newborn survival rates. The findings thus establish an etiologic link between bile acids and PTB, and open an avenue for developing etiology-based therapies to prevent or delay PTB.

1 July 2018 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
LVLeila Valanejad
Leila Valanejad
MGMwlod Ghareeb
Mwlod Ghareeb
SSStephanie Shiffka
Stephanie Shiffka
CNChristina Nadolny
Christina Nadolny
YCYuan Chen
Yuan Chen
RDRuitang Deng
Ruitang Deng

26 January 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LVLeila Valanejad
Leila Valanejad
CNChristina Nadolny
Christina Nadolny
SSStephanie Shiffka
Stephanie Shiffka
YCYuan Chen
Yuan Chen
SYSangmin You
Sangmin You
RDRuitang Deng
Ruitang Deng
Δ4-3-oxosteroid 5β-reductase is member D1 of the aldo-keto reductase family 1 (AKR1D1), which catalyzes 5β-reduction of molecules with a 3-oxo-4-ene structure. Bile acid intermediates and most of the steroid hormones carry the 3-oxo-4-ene structure. Therefore, AKR1D1 plays critical roles in both bile acid synthesis and steroid hormone metabolism. Currently our understanding on transcriptional regulation of AKR1D1 under physiological and pathological conditions is very limited. In this study, we investigated the regulatory effects of primary bile acids, chenodeoxycholic acid (CDCA) and cholic acid (CA), on AKR1D1 expression. The expression levels of AKR1D1 mRNA and protein in vitro and in vivo following bile acid treatments were determined by real-time PCR and Western blotting. We found that CDCA markedly repressed AKR1D1 expression in vitro in human hepatoma HepG2 cells and in vivo in mice. On the contrary, CA significantly upregulated AKR1D1 expression in HepG2 cells and in mice. Further mechanistic investigations revealed that the farnesoid x receptor (FXR) signaling pathway was not involved in regulating AKR1D1 by bile acids. Instead, CDCA and CA regulated AKR1D1 through the mitogen-activated protein kinases/c-Jun N-terminal kinases (MAPK/JNK) signaling pathway. Inhibition of the MAPK/JNK pathway effectively abolished CDCA and CA-mediated regulation of AKR1D1. It was thus determined that AKR1D1 expression was regulated by CDCA and CA through modulating the MAPK/JNK signaling pathway. In conclusion, AKR1D1 expression was differentially regulated by primary bile acids through negative and positive feedback mechanisms. The findings indicated that both bile acid concentrations and compositions play important roles in regulating AKR1D1 expression, and consequently bile acid synthesis and steroid hormone metabolism.

1 January 2021
Verified
Journal Article
Closed access
CNChristina Nadolny
Christina Nadolny
XZXinmu Zhang
Xinmu Zhang
QCQiwen Chen
Qiwen Chen
SHSyed F. Hashmi
Syed F. Hashmi
WAWinifer Ali
Winifer Ali
RDRuitang Deng
Ruitang Deng

20 November 2019
Verified
Book Chapter
Open access
PDF file
XZXinmu Zhang
Xinmu Zhang
RDRuitang Deng
Ruitang Deng
Bile acids are synthesized in the liver and tightly regulated through the enterohepatic circulation. Recent studies reveal that bile acids serve as hormone-like signaling molecules to activate nuclear receptors, notably farnesoid X receptor (FXR), regulating metabolic homeostasis of bile acids, cholesterol, lipids, and glucose. A connection between bile acids and nonalcoholic fatty liver disease (NAFLD) has long been recognized. Although inconsistent or even contradictory results are reported, a large body of evidence from clinical as well as preclinical studies demonstrates that bile acid homeostasis is disrupted in patients with NAFLD. The bile acid dysregulation gets worsening as NAFLD progresses from early stage simple steatosis to late stage nonalcoholic steatohepatitis (NASH) and NASH with fibrosis. As the risk factors for NAFLD, obesity and insulin resistance, which are often associated with NAFLD, contribute to the dysregulation of bile acids in patients with NAFLD. Total serum and fecal bile acid concentrations are mostly elevated in patients with NAFLD as a result of increased bile acid synthesis, elevated hepatic bile acids, and upregulation of bile acid transporters. The two negative feedback regulatory pathways for bile acid synthesis, FXR/SHP (small heterodimer partner) and fibroblast growth factor-19 (FGF19)/FGF receptor-4 (FGFR4), are impaired in patients with NAFLD.

15 June 2023
Verified
Journal Article
Closed access
XZXinmu Zhang
Xinmu Zhang
CNChristina Nadolny
Christina Nadolny
QCQiwen Chen
Qiwen Chen
WAWinifer Ali
Winifer Ali
SHSyed F. Hashmi
Syed F. Hashmi
RDRuitang Deng
Ruitang Deng